NASDAQ
No company description is available yet.
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
Where price sits today against its own history. A description, not a forecast.
Average return in each calendar month, Feb 28, 2025 to Sep 30, 2026. 2 years is 2 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
| Year | J | F | M | A | M | J | J | A | S | O | N | D | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −8 | −0 | −1 | −4 | −13 | −12 | −1 | −2 | −5 | −38% | |||
| 2025 | +8 | +15 | +11 | −0 | +61 | −6 | +15 | −8 | −14 | −3 | −19 | +48% |
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
The company received a prestigious Breakthrough Therapy Designation from China's regulatory authority for an important indication (treatment-naïve CLL/SLL), which accelerates development timelines and provides a pathway to priority review and conditional approval. This represents significant regulatory validation and de-risks the development program, supporting potential future revenue generation and market expansion.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.